Subject(s)
Biomedical Research/economics , Coronavirus Infections , Pandemics , Pneumonia, Viral , Betacoronavirus , COVID-19 , Humans , SARS-CoV-2Subject(s)
Biomedical Research , COVID-19 , Coronavirus , Financing, Organized , National Institutes of Health (U.S.) , Humans , Biomedical Research/economics , Biomedical Research/legislation & jurisprudence , Biomedical Research/trends , COVID-19/epidemiology , COVID-19/transmission , COVID-19/virology , National Institutes of Health (U.S.)/economics , National Institutes of Health (U.S.)/legislation & jurisprudence , Politics , United States , Viral Zoonoses/epidemiology , Viral Zoonoses/transmission , Viral Zoonoses/virology , AnimalsABSTRACT
Investment, collaboration, and coordination have been key.
Subject(s)
Biomedical Research , COVID-19 , Humans , Biomedical Research/economics , Biomedical Research/trends , COVID-19/prevention & control , COVID-19/therapy , National Institutes of Health (U.S.) , Investments , International Cooperation , COVID-19 Vaccines , Clinical Trials as TopicSubject(s)
Budgets , Federal Government , Science/economics , Biomedical Research/economics , COVID-19/diagnosis , COVID-19/economics , COVID-19/prevention & control , COVID-19/therapy , Global Warming/economics , Global Warming/prevention & control , Humans , Public Health/economics , Racism/economics , Racism/prevention & control , Renewable Energy/economics , United States , United States Environmental Protection Agency/economics , United States National Aeronautics and Space Administration/economicsABSTRACT
Major funding effort aims to address weaknesses exposed by COVID-19 pandemic.
Subject(s)
Biomedical Research , COVID-19 , Neglected Diseases , Pandemics , Vaccines , Humans , COVID-19/prevention & control , Japan , Pandemics/prevention & control , Biomedical Research/economics , Biomedical Research/trends , Neglected Diseases/prevention & control , Neglected Diseases/virologyABSTRACT
New investigative panels will delve into pandemic origins and research ties with China.
Subject(s)
COVID-19 , Pandemics , Politics , China , COVID-19/epidemiology , Research Personnel , Biomedical Research/economics , Capital FinancingSubject(s)
Biomedical Research/economics , Biomedical Research/legislation & jurisprudence , Budgets/legislation & jurisprudence , COVID-19 , International Cooperation/legislation & jurisprudence , Research Personnel , Research Support as Topic/legislation & jurisprudence , COVID-19/economics , COVID-19/epidemiology , Clinical Trials as Topic/economics , Humans , Research Personnel/economics , Research Personnel/psychology , Uncertainty , United Kingdom , Universities/economicsABSTRACT
For the past 20 years, the notion of bioterror has been a source of considerable fear and panic worldwide. In response to the terror attacks of 2001 in the USA, extensive research funding was awarded to investigate bioterror-related pathogens. The global scientific legacy of this funding has extended into the present day, highlighted by the ongoing COVID-19 pandemic. Unsurprisingly, the surge in biodefence-related research and preparedness has been met with considerable apprehension and opposition. Here, we briefly outline the history of modern bioterror threats and biodefence research, describe the scientific legacy of biodefence research by highlighting advances pertaining to specific bacterial and viral pathogens, and summarise the future of biodefence research and its relevance today. We sought to address the sizeable question: have the past 20 years of investment into biodefence research and preparedness been worth it? The legacy of modern biodefence funding includes advancements in biosecurity, biosurveillence, diagnostics, medical countermeasures, and vaccines. In summary, we feel that these advances justify the substantial biodefence funding trend of the past two decades and set a precedent for future funding.
Subject(s)
Biomedical Research/economics , Bioterrorism/prevention & control , Financial Support , Humans , Investments , Risk Assessment , Vaccines/immunologySubject(s)
Biomedical Research/economics , Capital Financing , Cultural Diversity , Fund Raising , HumansSubject(s)
COVID-19 , Diplomacy , Leadership , National Institutes of Health (U.S.)/organization & administration , Racism/prevention & control , Biomedical Research/economics , Biomedical Research/legislation & jurisprudence , Biomedical Research/organization & administration , COVID-19/complications , COVID-19/epidemiology , China , Female , Fetal Research/legislation & jurisprudence , Financing, Organized , Humans , International Cooperation , Male , National Institutes of Health (U.S.)/economics , Research Support as Topic , United States , Post-Acute COVID-19 SyndromeABSTRACT
Recent studies have shown that relatively few MD, DO, and underrepresented in medicine (URM) students and physicians are matching into pathology residency in the United States (US). In the 2021 Main Residency Match, just 33.6% of filled pathology residency positions were taken by senior year students at US allopathic medical schools. This has been attributed to the fact that pathology is not a required rotation in most US medical schools, pathology is often taught in an integrated curriculum in the US where is does not stand out as a distinct field, and because the COVID-19 pandemic led to a suspension of in-person pathology rotations and electives. Ultimately, many US medical students fail to consider pathology as a career pathway. The objective of this article is to provide medical students with basic information, in the form of frequently asked questions (FAQs), about pathology training and career opportunities. This was accomplished by forming a team of MD and DO pathology attendings, pathology trainees, and a medical student from multiple institutions to create a pathology guide for medical students. This guide includes information about post-sophomore fellowships, 5 major pathology residency tracks, more than 20 fellowship pathways, and allopathic and osteopathic board examinations. This guide also contains photographs and descriptions of major pathology sub-specialties, including the daily and on-call duties and responsibilities of pathology residents. The exciting future of pathology is also discussed. This guide supports the agenda of the College of American Pathologists' (CAP) Pathologist Pipeline Initiative to improve student recruitment into pathology.
Subject(s)
Career Choice , Fellowships and Scholarships , Internship and Residency , Pathology/education , Students, Medical , Biomedical Research/economics , Biomedical Research/education , Humans , Pathology/economics , Pathology/methods , Periodicals as Topic , Research Support as Topic , Specialization , United StatesSubject(s)
Biomedical Research , COVID-19 , Disease Transmission, Infectious , Education, Medical, Graduate , Faculty, Medical , Research Personnel , Research Support as Topic , Ambulatory Care , Biomedical Research/economics , Biomedical Research/education , COVID-19/prevention & control , COVID-19/transmission , COVID-19/virology , COVID-19 Vaccines , Carrier State/prevention & control , Child , Child Behavior , Disease Transmission, Infectious/prevention & control , Disease Transmission, Infectious/statistics & numerical data , Education, Distance , Health Equity , Healthcare Disparities , Humans , Internship and Residency , Mentoring , SARS-CoV-2 , Treatment OutcomeABSTRACT
Access to vaccines against covid-19 is a very topical issue. On the one hand, we are suffering from supply problems and inadequate availability of doses both nationally and internationally. On the other hand, public health needs do not coincide with those of the market economy: the need to vaccinate the entire world population to overcome the pandemic cannot be satisfied due to market rules and limits in production processes. The result is a radical inequality in access to vaccines. We are aware of the delicate balance between health and economy: the latter cannot ignore the former. Also for this reason, the demand for greater equity in access to vaccines is growing: the race for innovation may not be hindered by a targeted relaxation of the rules on intellectual property during a pandemic health emergency.
Subject(s)
COVID-19 Vaccines/supply & distribution , COVID-19/prevention & control , Drug Development , Intellectual Property , Biomedical Research/economics , COVID-19 Vaccines/economics , Diffusion of Innovation , Global Health , Healthcare Disparities , Humans , Italy , Needs Assessment , Patents as Topic , Public Health , Research Support as Topic/economics , Vaccination CoverageABSTRACT
With billions of dollars in research and development (R&D) funding continuing to be invested, the novel coronavirus disease 2019 (COVID-19) has become into a singular focus for the scientific community. However, the collective response from the scientific communities have seen poor return on investment, particularly for therapeutic research for COVID-19, revealing the existing weaknesses and inefficiencies of the clinical trial enterprise. In this article, we argue for the importance of structural changes to existing research programs for clinical trials in light of the lessons learned from COVID-19.
Subject(s)
Biomedical Research/organization & administration , COVID-19/epidemiology , COVID-19/therapy , Clinical Protocols/standards , Clinical Trials as Topic/organization & administration , Biomedical Research/economics , Biomedical Research/standards , Clinical Trials as Topic/economics , Clinical Trials as Topic/standards , Humans , SARS-CoV-2ABSTRACT
Brains are indispensable drivers of human progress. Why not invest more heavily in them? We seek to place Brain Capital at the center of a new narrative to fuel economic and societal recovery and resilience.
Subject(s)
Brain , Capital Financing , Health Promotion , Interdisciplinary Research , Neurosciences , Biomedical Research/economics , Health Promotion/economics , Health Promotion/methods , Health Promotion/organization & administration , Humans , Interdisciplinary Communication , Interdisciplinary Research/economics , Interdisciplinary Research/organization & administration , Neurosciences/economicsSubject(s)
Biomedical Research , COVID-19 , Cardiovascular Diseases , Research/organization & administration , Biomedical Research/economics , Biomedical Research/trends , COVID-19/mortality , COVID-19/prevention & control , Cardiovascular Diseases/epidemiology , Cardiovascular Diseases/therapy , Communicable Disease Control/methods , Humans , Needs Assessment , Organizational Innovation , Resource Allocation , SARS-CoV-2 , United KingdomABSTRACT
The proposed triple aim of health care-enhanced patient experience, improved population health, and reduced per capita costs-can be applied to clinical research. A triple aim for clinical research would (1) improve the individual research participant's experience; (2) promote the health of populations; and (3) reduce per capita costs of clinical research. Such an approach is possible by designing trials around the needs of participants rather than sites, embracing digital measures of health, and advancing decentralized studies. Recent studies, including those evaluating therapies for COVID-19, have demonstrated the value of such an approach. Accelerating the adoption of these methods can help fulfill this new triple aim of clinical research.